Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients

Epithelial growth factor receptor (EGFR) mutations are present in 10%–26% of non-small cell lung cancer (NSCLC) tumors and are associated with the response to tyrosine kinase inhibitors (TKIs). This study aimed to detect and quantify the presence of circulating tumor cells (CTCs) in EGFR-mutant NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Baohong, Qin, Aiying, Zhang, Kongyuan, Ren, Haipeng, Liu, Shuzhen, Liu, Xiaolei, Pan, Xiangpo, Yu, Guohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840965/
https://www.ncbi.nlm.nih.gov/pubmed/28474575
http://dx.doi.org/10.3727/096504017X14928634401178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840965/
https://www.ncbi.nlm.nih.gov/pubmed/28474575
http://dx.doi.org/10.3727/096504017X14928634401178

Ejemplares similares